Skip to main content
Figure 4 | Molecular Neurodegeneration

Figure 4

From: The mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease

Figure 4

Everolimus does not affect LC3BII levels in mouse HD brain. There is no significant effect of everolimus on normalized LC3BII levels in striatum and cortex (A). There is a trend towards increased normalized LC3BII levels in muscle of everolimus treated R6/2 mice (global p-value = 0.12) (B). Mice were treated from 4-12 weeks and sacrificed 4-hours after the last dose. X-axes show genotype-dose combinations. TG = transgenic, WT = wild-type. n = 10.

Back to article page

Molecular Neurodegeneration

ISSN: 1750-1326